News
Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors
GolbalNewswire | 3/21/24
Nectin Therapeutics Adds Combination Therapy Arm and Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent
PR Newswire | 12/18/2023
March Biosciences and Cancer Focus Fund Announce $4.8 Million Investment to Support a Phase 2 Clinical Trial of Novel CAR-T Therapy for T-Cell Lymphoma
March Biosciences | 11/9/23
Cancer Focus Fund invests $4.8M into Houston-based March Biosciences
March Biosciences | 11/9/23
ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS‑001 in Relapsed or Refractory Advanced Solid Tumors
ImmunoGenesis | 9/28/23
Houston Oncology Summit: MD Anderson’s VP of industry relations talks about partnering (Video)
BiotechTV | 09/21/23
Houston Oncology Summit: How the Cancer Focus Fund Can Help Small Biotechs Get Into Phase 1 Studies (Video)
BiotechTV | 09/21/23
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors
ImmunoGenesis | 8/31/23
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
BioSpace | 05/16/2023
Ovarian Cancer Survivor: Immunotherapy Clinical Trial Saved
MD Anderson Cancer Center | 5/2/23
ISA Pharmaceuticals And Cancer Focus Fund Announce $5 Million Investment To Support First- In-Human Trial Of ISA’s Novel Immunotherapy ISA103 In Uveal Melanoma
PR Newswire | 01/04/23
Drug Could Bring Immunotherapy To Millions Of Cancer Patients
No Camels | 12/29/22
Israeli Biotech Company Begins Trial For Cancer Immuno-Oncology Solution
The Jerusalem Post | 11/30/22
MD Anderson VC Arm Joins $25M Funding Round For Cancer Drug Company
Becker’s Healthcare | 11/30/22
Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors
PR Newswire | 11/30/22
Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy
PR Newswire | 03/07/22
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
PR Newswire | 02/17/2022
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers
PR Newswire | 05/26/2021
Mereo and Focus Fund Announce Etigilimab partnership with MD Anderson
Mereo BioPharma | 04/30/21
MD Anderson Brings Underdogs into the Fight Against Cancer with Focus Fund
BioSpace | 10/21/20
Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials
PR Newswire | 10/20/20